Method
Indications of retrospective usage, responses and rates of intravenous
immunoglobulin preparations are evaluated in the Hematology Clinic of
our hospital and usage with various indications between January 2010 and
January 2020 were attempted to be put forth. The patient data in the
study were accessed and analyzed through the hospital information
processing system after the approval of the hospital ethics committee.
When the responses were evaluated, the target values were handled and
the response status was revealed. Our targets for treatment responses
were as follows: For immune thrombocytopenia, the platelet count target
was 30000 x 103/µL and above; no hospitalization need
for secondary hypogammaglobulinemia; no replacement need for hemolytic
anemia after IVIG and a hemoglobin level above 8 g/dl.